Final Contrast Imaging Guidance Addresses Some, Not All, Industry Critiques
This article was originally published in The Gray Sheet
Executive Summary
FDA's final guidance on the intersecting regulatory pathways of imaging devices and contrast agents clarifies which marketing submissions are needed for various product changes, but still does not address data requirements for specific indications, such as breast cancer imaging
You may also be interested in...
FDA Unveils Adverse Event Reporting Rules For Combination Products
FDA says its proposed adverse event reporting requirements for combination products will help manufacturers navigate the intricate array of reporting requirements for deaths and injuries
Imaging Industry Wants A Rewrite On FDA Contrast Indication Guidance
An FDA draft guideline outlining the regulatory pathway for imaging equipment makers seeking to add new contrast agent indication labeling needs an overhaul to include more explicit guidance for sponsors, manufacturers say
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.